Advertisement
News
Advertisement

Enlyton, Ltd. Awarded National Cancer Institute SBIR Phase I Contract for Tumor Targeting Agent for SPECT Imaging of Cancer

Tue, 09/18/2012 - 9:07am
The Associated Press

COLUMBUS, Ohio--(BUSINESS WIRE)--Sep 18, 2012--Enlyton, Ltd., a technology leader in the development of cancer-specific tumor targeting agents for use in molecular imaging, has been awarded a Phase I Small Business Innovation Research (SBIR) contract in the amount of $249,525 from the National Cancer Institute (NCI). The Phase I contract, which will cover approximately 10% of the total project cost, will be used to complete pre-clinical development of Enlyton’s antibody-based tumor targeting agent for SPECT imaging of adenocarcinomas (e.g., colorectal, esophageal, stomach, lung, ovarian, pancreatic).

Current cancer imaging and detection methods often fail to provide a clear picture of the extent of disease. SPECT (single photon emission computed tomography) is a sizeable market with a large base of installed scanners that has not been adequately supported for use in cancer imaging. Recent developments, e.g., SPECT/CT (computed tomography) fused imaging technology with attenuation correction, have improved SPECT performance and its clinical relevance for cancer imaging. The work of this contract will construct an antibody-based targeting agent that can rapidly accumulate in tumors while clearing from circulation quickly, and enable dosing and imaging within 24 hours using existing SPECT and SPECT/CT imaging platforms.

“Funding from this NCI SBIR contract will enable Enlyton, in collaboration with development partners Applied Biomolecular Technologies, Quanta BioDesign, and The Ohio State University, to complete this effort, and initiate the production of clinical grade antibody in the third quarter 2013”, added Enlyton CEO Jeff Bergen.

About Enlyton, Ltd.

Enlyton is integrating proprietary antibody technology into cancer-specific, antigen-directed targeting agents for use in cancer imaging, intraoperative cancer detection, and post-operative disease prognosis. Enlyton’s goal is to provide more accurate disease information, enabling oncologists to better determine the course of therapy, save lives, and reduce the overall cost of cancer treatment.

CONTACT: Enlyton, Ltd.

Jeff Bergen, 614-888-9220 Jeff.bergen@enlyton.net KEYWORD: UNITED STATES NORTH AMERICA OHIO INDUSTRY KEYWORD: SURGERY HEALTH BIOTECHNOLOGY MEDICAL DEVICES ONCOLOGY PHARMACEUTICAL RADIOLOGY FDA SOURCE: Enlyton, Ltd. Copyright Business Wire 2012 PUB: 09/18/2012 09:07 AM/DISC: 09/18/2012 09:07 AM http://www.businesswire.com/news/home/20120918005405/

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading